Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 13Gastrointestinal 7Breast 3Thoracic 2Sarcoma 1Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Sarcoma 63Osteosarcoma 16Leiomyosarcoma 16Neoplasm Metastasis 10Pancreatic Neoplasms 9Breast Neoplasms 9Bone Neoplasms 8Rhabdomyosarcoma 6Ovarian Neoplasms 6Neoplasms 6Colorectal Neoplasms 6Small Cell Lung Carcinoma 5Sarcoma, Ewing 5Liposarcoma 5Head and Neck Neoplasms 5Colonic Neoplasms 5Sarcoma, Synovial 4Prostatic Neoplasms 4Melanoma 4Histiocytoma, Malignant Fibrous 4Hemangiosarcoma 4Chondrosarcoma 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Recurrence 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Gastrointestinal Stromal Tumors 3Esophageal Neoplasms 3Dermatofibrosarcoma 3

Interventions

Paclitaxel 7Specimen Handling 6Radiotherapy 4Magnetic Resonance Spectroscopy 4Biopsy 4pembrolizumab 3Taxes 3Nivolumab 3Carboplatin 3trastuzumab deruxtecan 2olaparib 2ceralasertib 2aflibercept 2X-Rays 2Psychiatric Rehabilitation 2Irinotecan 2Ipilimumab 2Immunoglobulin G 2Ifosfamide 2Gene Expression Profiling 2Fulvestrant 2Filgrastim 2Fentanyl 2Doxorubicin 2Bevacizumab 2trifluridine tipiracil drug combination 1toripalimab 1tinostamustine 1spartalizumab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Gemcitabine × Sarcoma × Clear all
NCT02632448 2025-05-02

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma Inc.

Phase 1/2 Completed
229 enrolled
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡